Morgan Stanley’s fourth Asia private equity fund is mainly targeting deals in China. It has a South Korean and an Indian transaction already in the bag.
The Chinese manufacturer of cardio-cerebral vascular drugs raises $741 million by pricing its shares at 26.7 times next year's earnings, making it the most expensive new stock to list in Hong Kong this year.